Pulmonary Rota cap in pharma franchise in Manipur

Pulmonary Rota cap in PCD pharma franchise in Chandigarh

Pulmonary Rota cap in top pharma company in Sikkim

Pulmonary Rota cap in pcd pharma supplier in Bhopal

Pulmonary Rota capin phama franchise company in India
Pulmonary Rota cap in phama distributor in Patna

Home/Products /glycopyrronium-25mcg-formoterol-12mcg-budesonide-rota-cap

Buditerm GF Rota Capsule

Composition : Glycopyrronium (25mcg) + Formoterol (12mcg)+ Budesonide (400 mcg) Rota Capsule

Dosage Form : Rota cap

Packaging Type : in a bottle, silica gel,with carton

Packaging : 30 Capsules

Price : ₹549/-

Buditerm GF is a powerful inhalation therapy designed for the effective management of chronic obstructive pulmonary disease (COPD) and asthma. Each Rota Cap contains a carefully balanced combination of Glycopyrronium (25 mcg), Formoterol (12 mcg), and Budesonide (400 mcg). This unique formulation targets multiple pathways to provide comprehensive relief from respiratory symptoms, improving overall lung function and quality of life.

Glycopyrronium is an anticholinergic agent that helps to relax the muscles around the airways, leading to bronchodilation and improved airflow. Formoterol, a long-acting beta-agonist (LABA), complements this effect by stimulating beta-2 adrenergic receptors, further enhancing bronchodilation and providing prolonged relief from wheezing and shortness of breath. Budesonide, an inhaled corticosteroid (ICS), works to reduce inflammation in the airways, addressing the underlying causes of asthma and COPD. Together, these three components create a synergistic effect that not only alleviates symptoms but also helps to prevent exacerbations.

Read More

About the Product

Buditerm GF is a powerful inhalation therapy designed for the effective management of chronic obstructive pulmonary disease (COPD) and asthma. Each Rota Cap contains a carefully balanced combination of Glycopyrronium (25 mcg), Formoterol (12 mcg), and Budesonide (400 mcg). This unique formulation targets multiple pathways to provide comprehensive relief from respiratory symptoms, improving overall lung function and quality of life.

Glycopyrronium is an anticholinergic agent that helps to relax the muscles around the airways, leading to bronchodilation and improved airflow. Formoterol, a long-acting beta-agonist (LABA), complements this effect by stimulating beta-2 adrenergic receptors, further enhancing bronchodilation and providing prolonged relief from wheezing and shortness of breath. Budesonide, an inhaled corticosteroid (ICS), works to reduce inflammation in the airways, addressing the underlying causes of asthma and COPD. Together, these three components create a synergistic effect that not only alleviates symptoms but also helps to prevent exacerbations.

Common side effects may include throat irritation, hoarseness, headache, and increased risk of respiratory infections. Some patients may also experience palpitations or muscle cramps. It is important to monitor for any unusual symptoms during treatment.

Glycopryl FB is indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults.

Glycopryl FB should be used only as directed by a healthcare professional. Do not exceed the recommended dosage, and consult a doctor if symptoms do not improve or worsen.

Store Glycopryl FB in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children to ensure safety.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation